Cargando…

Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores

BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) risk stratification in individuals with dysmetabolism is a major unmet need. Genetic predisposition contributes to non-alcoholic fatty liver disease (NAFLD). We aimed to exploit robust polygenic risk scores (PRS) that can be evaluated in the clin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bianco, Cristiana, Jamialahmadi, Oveis, Pelusi, Serena, Baselli, Guido, Dongiovanni, Paola, Zanoni, Irene, Santoro, Luigi, Maier, Silvia, Liguori, Antonio, Meroni, Marica, Borroni, Vittorio, D’Ambrosio, Roberta, Spagnuolo, Rocco, Alisi, Anna, Federico, Alessandro, Bugianesi, Elisabetta, Petta, Salvatore, Miele, Luca, Vespasiani-Gentilucci, Umberto, Anstee, Quentin M., Stickel, Felix, Hampe, Jochen, Fischer, Janett, Berg, Thomas, Fracanzani, Anna Ludovica, Soardo, Giorgio, Reeves, Helen, Prati, Daniele, Romeo, Stefano, Valenti, Luca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7987554/ https://www.ncbi.nlm.nih.gov/pubmed/33248170 http://dx.doi.org/10.1016/j.jhep.2020.11.024

Ejemplares similares

Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and fibrosis in individuals at high risk of nonalcoholic fatty liver disease
por: Dongiovanni, Paola, et al.
Publicado: (2018)

Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease
por: Pelusi, Serena, et al.
Publicado: (2016)

The rs599839 A>G Variant Disentangles Cardiovascular Risk and Hepatocellular Carcinoma in NAFLD Patients
por: Meroni, Marica, et al.
Publicado: (2021)

Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease
por: Pelusi, Serena, et al.
Publicado: (2019)

Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease
por: Donati, Benedetta, et al.
Publicado: (2017)

Inborn and acquired risk factors for severe liver disease in Europeans with type 2 diabetes from the UK Biobank
por: Tavaglione, Federica, et al.
Publicado: (2021)

MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals
por: Donati, Benedetta, et al.
Publicado: (2017)

Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women
por: Cherubini, Alessandro, et al.
Publicado: (2023)

miRNA Signature in NAFLD: A Turning Point for a Non-Invasive Diagnosis
por: Dongiovanni, Paola, et al.
Publicado: (2018)

Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker
por: Baselli, Guido Alessandro, et al.
Publicado: (2020)

An Overview of Hepatocellular Carcinoma Surveillance Focusing on Non-Cirrhotic NAFLD Patients: A Challenge for Physicians
por: Cespiati, Annalisa, et al.
Publicado: (2023)

TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models
por: Longo, Miriam, et al.
Publicado: (2021)

Impact of Sarcopenia and Myosteatosis in Non-Cirrhotic Stages of Liver Diseases: Similarities and Differences across Aetiologies and Possible Therapeutic Strategies
por: Cespiati, Annalisa, et al.
Publicado: (2022)

Mboat7 down-regulation by hyper-insulinemia induces fat accumulation in hepatocytes
por: Meroni, Marica, et al.
Publicado: (2020)

SUN-564 ATG7 Overexpression Results in Reduction of Hepatocellular Lipid Content in Vitro
por: Tavaglione, Federica, et al.
Publicado: (2020)

The KLB rs17618244 gene variant is associated with fibrosing MAFLD by promoting hepatic stellate cell activation
por: Panera, Nadia, et al.
Publicado: (2021)

MBOAT7 down-regulation by genetic and environmental factors predisposes to MAFLD
por: Meroni, Marica, et al.
Publicado: (2020)

mir-101-3p Downregulation Promotes Fibrogenesis by Facilitating Hepatic Stellate Cell Transdifferentiation During Insulin Resistance
por: Meroni, Marica, et al.
Publicado: (2019)

Expanding the phenotypic spectrum of non-alcoholic fatty liver disease and hypertriglyceridemia
por: Meroni, Marica, et al.
Publicado: (2022)

Genetics, Immunity and Nutrition Boost the Switching from NASH to HCC
por: Dongiovanni, Paola, et al.
Publicado: (2021)

The A736V TMPRSS6 Polymorphism Influences Hepatic Iron Overload in Nonalcoholic Fatty Liver Disease
por: Valenti, Luca, et al.
Publicado: (2012)

PSD3 downregulation confers protection against fatty liver disease
por: Mancina, Rosellina M., et al.
Publicado: (2022)

PD-1/PD-L1 Immuno-Mediated Therapy in NAFLD: Advantages and Obstacles in the Treatment of Advanced Disease
por: Lombardi, Rosa, et al.
Publicado: (2022)

Lack of association between peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control study
por: Dongiovanni, Paola, et al.
Publicado: (2010)

The I148M PNPLA3 variant mitigates niacin beneficial effects: How the genetic screening in non-alcoholic fatty liver disease patients gains value
por: Paolini, Erika, et al.
Publicado: (2023)

Pathophysiology of Non Alcoholic Fatty Liver Disease
por: Petta, Salvatore, et al.
Publicado: (2016)

Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment
por: Dongiovanni, Paola, et al.
Publicado: (2013)

Lack of genetic evidence that fatty liver disease predisposes to COVID-19
por: Valenti, Luca, et al.
Publicado: (2020)

PNPLA3 I148M Polymorphism, Clinical Presentation, and Survival in Patients with Hepatocellular Carcinoma
por: Valenti, Luca, et al.
Publicado: (2013)

α-Lipoic Acid Improves Hepatic Metabolic Dysfunctions in Acute Intermittent Porphyria: A Proof-of-Concept Study
por: Longo, Miriam, et al.
Publicado: (2021)

A Nutrigenomic Approach to Non-Alcoholic Fatty Liver Disease
por: Dongiovanni, Paola, et al.
Publicado: (2017)

Serum coding and non‐coding RNAs as biomarkers of NAFLD and fibrosis severity
por: Di Mauro, Stefania, et al.
Publicado: (2019)

Boosting pigment epithelial-derived factor: a promising approach for the treatment of early portal hypertension
por: Vespasiani-Gentilucci, Umberto, et al.
Publicado: (2015)

Non-Invasive Diagnostic Test for Advanced Fibrosis in Adolescents With Non-Alcoholic Fatty Liver Disease
por: Mosca, Antonella, et al.
Publicado: (2022)

The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids
por: Prill, Sebastian, et al.
Publicado: (2019)

Promoting genetics in non-alcoholic fatty liver disease: Combined risk score through polymorphisms and clinical variables
por: Vespasiani-Gentilucci, Umberto, et al.
Publicado: (2018)

Risk of Obstructive Sleep Apnea with Daytime Sleepiness Is Associated with Liver Damage in Non-Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease
por: Pulixi, Edoardo Alessandro, et al.
Publicado: (2014)

Metabolic and genetic determinants for progression to severe liver disease in subjects with obesity from the UK Biobank
por: De Vincentis, Antonio, et al.
Publicado: (2021)

Low Lipoprotein(a) Levels Predict Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
por: Meroni, Marica, et al.
Publicado: (2021)

The role of intestinal microbiota in the pathogenesis of NAFLD: starting points for intervention
por: Vespasiani-Gentilucci, Umberto, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_eoe469dicl1e6mqmal81grddig